ALERT: Blood Pressure Pills RECALLED

Warning sign among assorted pills and capsules — Photo: Teacher Photo / Shutterstock

Two recalls in three months pulled more than 25,000 bottles of a common blood pressure drug after tablets failed to dissolve as required.

Story Snapshot

Chlorthalidone 25 mg tablets were recalled nationwide after failing dissolution tests.
June 5 recall covered 11,460 bottles; Sept. 3 recall added 13,567 more.
The September batch was RISA24002, expiring April 2027; the Food and Drug Administration labeled it Class II on Sept. 17.
No injuries had been reported at the time of the initial recall.

What triggered the back-to-back recalls

Inventia Healthcare Limited initiated two nationwide recalls of Chlorthalidone Tablets, United States Pharmacopeia, 25 milligrams, after the drug failed to meet dissolution specifications. The first recall began June 5 and covered 11,460 bottles. The second recall began Sept. 3 and added 13,567 bottles.

The Food and Drug Administration later classified the September action as a Class II recall on Sept. 17, meaning the chance of serious harm is remote and effects should be temporary or reversible.

Widely used blood pressure medication recalled nationwide https://t.co/Y3YjWnZsOZ #FoxBusiness

— Greg Shields (@GregShield83077) September 30, 2026

Officials and company statements summarized in news reports said the problem is simple but serious: some tablets may not dissolve properly in the body, which can reduce how well they lower blood pressure.

This is not a contamination scare or a mix-up. It is a performance failure that hides in plain sight. A pill can look fine and still deliver too little medicine if it does not break down as designed. That is why regulators pull stock before patients notice the gap.

Which product, lots, and how to recognize them

The product is Chlorthalidone Tablets, United States Pharmacopeia, 25 milligrams, in 100-count bottles distributed nationwide. Reports say the September recall centers on batch RISA24002 with an expiration date of April 2027.

Earlier coverage of the June action noted the same tablet strength and described both 100-count and some 1,000-count bottles in distribution channels. Pharmacies and wholesalers were advised to quarantine the affected bottles and return them per recall notices.

For patients, the right next step is routine and safe. Do not stop your blood pressure medicine on your own. Call your pharmacist to check your bottle’s label and lot number. If your lot is affected, ask for a replacement.

Then call your prescriber if you have seen higher blood pressure readings or swelling, since those could signal your dose fell short. These simple checks protect health without creating a new risk from a sudden stop in therapy.

Why dissolution failures matter for real-world blood pressure control

Dissolution testing measures how fast and how completely a tablet releases its drug in set lab conditions. For a water pill like chlorthalidone, release timing supports steady blood pressure control during the day.

When a batch fails dissolution, some tablets may release too slowly or not enough drug, dulling the effect. That can mean creeping blood pressure, more fluid retention, and higher strain on the heart over time. The risk is subtle, but it is real enough to warrant a recall.

Inventia Healthcare has initiated a nationwide recall of more than 25,000 bottles of chlorthalidone tablets. The recall follows concerns regarding dissolution flaws identified during testing, which could impact the medication's effectiveness. pic.twitter.com/07f6W7Rdd9

— Azat TV (@azattelevision) September 30, 2026

Patients keep their end by taking pills as directed. Manufacturers must do the same by meeting every standard, every time. The Food and Drug Administration’s Class II label signals a low chance of severe harm, not a green light to shrug. Two recalls in a season should prompt tight corrective action, fresh oversight, and fast, transparent updates until confidence is restored.